WINT Windtree Therapeutics

Windtree Therapeutics, Inc. engages in the manufacture and development of products for infants and respiratory diseases. It focuses on producing of surfactant replacement therapies for patients with respiratory disease and neonatology for the improvement of respiratory distress syndrome for infants. The company was founded by Evan Myrianthopoulos and James S. Kuo on November 6, 1992 and is headquartered in Warrington, PA.
Company profile
Ticker
WINT, WINTW
Exchange
Website
CEO
Craig E. Fraser
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Bio-Techne • Enzon Pharmaceuticals • Denali Therapeutics • Allogene Therapeutics ...
Former names
ANSAN INC, ANSAN PHARMACEUTICALS INC, DISCOVERY LABORATORIES INC /DE/
SEC CIK
Corporate docs
IRS number
943171943
WINT stock data
()
News
Stocks That Hit 52-Week Lows On Friday
16 Apr 21
Insider Buys Windtree Therapeutics Stock
6 Apr 21
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
31 Mar 21
34 Stocks Moving in Wednesday's Pre-Market Session
31 Mar 21
Windtree Therapeutics Q4 EPS $(0.44) Down From $(0.16) YoY
29 Mar 21
Press releases
Thinking about buying stock in CASI Pharmaceuticals, Windtree Therapeutics, ChargePoint Holdings, FreightCar America, or AzurRx BioPharma?
31 Mar 21
Windtree Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results and Provides Key Business Updates
29 Mar 21
Windtree Therapeutics Announces Closing of $30.0 Million Public Offering
25 Mar 21
Windtree Therapeutics Announces Pricing of $30.0 Million Public Offering
23 Mar 21
Windtree Therapeutics Announces Proposed Public Offering of Common Stock and Warrants
22 Mar 21
Investment data
Securities sold
Number of investors
Calendar
29 Mar 21
17 Apr 21
31 Dec 21
Financial summary
Quarter (USD) |
Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) |
Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Financial data from company earnings reports.
Cash burn rate (estimated) | Burn method: Change in cash | Burn method: Operating income/loss | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 17.08M | 17.08M | 17.08M | 17.08M | 17.08M | 17.08M |
Cash burn (monthly) | 1.76M | 470.67K | 2.32M | 2.53M | 1.51M | 2.11M |
Cash used (since last report) | 6.27M | 1.68M | 8.27M | 9.01M | 5.39M | 7.52M |
Cash remaining | 10.82M | 15.41M | 8.81M | 8.08M | 11.69M | 9.56M |
Runway (months of cash) | 6.2 | 32.7 | 3.8 | 3.2 | 7.7 | 4.5 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
7 Apr 21 | Eric Curtis | Common Stock | Buy | Aquire P | No | No | 2.5172 | 791 | 1.99K | 1,291 |
6 Apr 21 | Fraser Craig | Common Stock | Buy | Aquire P | No | No | 2.57 | 500 | 1.29K | 28,298 |
5 Apr 21 | Fraser Craig | Common Stock | Buy | Aquire P | No | No | 2.5799 | 1,000 | 2.58K | 27,798 |
1 Apr 21 | Fraser Craig | Common Stock | Buy | Aquire P | No | No | 2.4587 | 500 | 1.23K | 26,798 |
31 Mar 21 | Fraser Craig | Common Stock | Buy | Aquire P | No | No | 2.3199 | 500 | 1.16K | 26,298 |
Institutional ownership Q4 2020
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
2.7% owned by funds/institutions
13F holders |
Current |
---|---|
Total holders | 15 |
Opened positions | 2 |
Closed positions | 2 |
Increased positions | 1 |
Reduced positions | 4 |
13F shares |
Current |
---|---|
Total value | 3.64M |
Total shares | 709.09K |
Total puts | 0 |
Total calls | 450K |
Total put/call ratio | – |
Largest owners |
Shares | Value |
---|---|---|
Vanguard | 276.53K | $1.42M |
Millennium Management | 107.51K | $552K |
Kepos Capital | 90K | $462K |
NTRS Northern Trust | 72.39K | $371K |
Frontier Wealth Management | 60K | $308K |
tru Independence | 60K | $308K |
Deerfield Management | 20.15K | $103K |
Paloma Partners Management | 18.47K | $95K |
Tower Research Capital | 3.58K | $19K |
UBS UBS Group AG - Registered Shares | 367 | $2K |
Content analysis
?
Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
advocate, Africa, agenda, AMP, analogy, androstane, BARDA, bargaining, Baricitinib, BBA, Biden, Biomedical, Bipartisan, broaden, bulk, card, Cardiology, Carlo, ceiling, Changshu, commensurate, compelled, Congressional, contradictory, departure, dissemination, Distinguishing, donut, driven, endeavor, enrichment, EUA, Evan, exacerbated, exert, fight, filtration, fit, flux, gap, genuine, Gung, Hamill, heard, Hefei, heightened, HF, HFpEF, Hg, hole, home, hypoperfusion, hypothecate, illustrative, incentivizing, IVDR, Judge, Ladenburg, Leslie, lethal, lockup, Loh, MDR, mm, Monte, motivate, neutralizing, Oppenheimer, outlook, outreach, Overallotment, PF, PolyPeptide, presumption, problem, prompted, pure, ratably, ready, rebate, receptor, reengage, reinvest, Relief, remanded, remdesivir, reopening, repay, repayable, repayment, repealed, rescue, reward, rhythm, Robert, rural, safeguard, SciAnda, Scott, sequence, sequester, serotype, shift, solution, South, speed, stable, stimulating, subscription, syncytial, Taxpayer, Thalmann, theft, trillion, Trump, unconstitutional, underwriting, underwritten, undo, unusual, unwanted, vaccine, viral, virtual, workplace, write
Removed:
accelerated, accelerating, accreted, achievable, Allergy, allocating, attached, categorized, circumvention, cisplatin, clinic, Codification, cold, Commonwealth, comprise, conserve, context, countermeasure, defer, division, Eleison, eligibility, encouraged, expressed, extinguished, Farmaceutici, feature, hereto, ILC, immaterial, incomplete, Inferior, inhaled, Joseph, Leone, lipid, Mahady, match, multiplied, NIAID, nonbinding, OTC, OTCQB, Overview, participant, powered, PRC, premise, proportionately, pursued, quotation, reader, refrigeration, restructure, retention, retired, retrospective, routinely, SBIR, SPA, Steering, Subtopic, tightly, traded, unaudited, verified, waived
Financial reports
10-K
2020 FY
Annual report
29 Mar 21
10-Q
2020 Q3
Quarterly report
16 Nov 20
10-Q
2020 Q2
Quarterly report
14 Aug 20
10-Q
2020 Q1
Quarterly report
13 May 20
10-K
2019 FY
Annual report
2 Apr 20
NT 10-K
Notice of late annual filing
30 Mar 20
10-Q
2019 Q3
Quarterly report
14 Nov 19
10-Q
2019 Q2
Quarterly report
13 Aug 19
10-Q
2019 Q1
Quarterly report
20 May 19
NT 10-Q/A
Notice of late quarterly filing (amended)
16 May 19
Current reports
8-K
Windtree Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results and Provides Key Business Updates
29 Mar 21
8-K
Entry into a Material Definitive Agreement
24 Mar 21
8-K
Entry into a Material Definitive Agreement
22 Mar 21
8-K
Regulation FD Disclosure
19 Feb 21
8-K
Departure of Directors or Certain Officers
9 Feb 21
8-K
Departure of Directors or Certain Officers
31 Dec 20
8-K
Windtree Therapeutics Reports Third Quarter 2020
16 Nov 20
8-K
Windtree Announces First Patient Dosed in Phase 2 Study of Istaroxime for the Acute Treatment of Early Cardiogenic Shock in Heart Failure Patients
1 Oct 20
8-K
Other Events
29 Sep 20
8-K
Entry into a Material Definitive Agreement
17 Sep 20
Registration and prospectus
424B5
Prospectus supplement for primary offering
24 Mar 21
424B5
Prospectus supplement for primary offering
22 Mar 21
S-8
Registration of securities for employees
12 Feb 21
S-8
Registration of securities for employees
12 Feb 21
S-3
Shelf registration
17 Sep 20
424B4
Prospectus supplement with pricing info
21 May 20
S-1/A
2020 Q1
IPO registration (amended)
18 May 20
8-A12B
Registration of securities on exchange
15 May 20
S-1/A
IPO registration (amended)
13 May 20
S-1/A
2019 FY
IPO registration (amended)
6 May 20
Proxies
DEF 14C
Information statement
29 Dec 20
DEF 14C
Information statement
18 Jul 19
PRE 14C
Preliminary information
24 Jun 19
DEF 14C
Information statement
31 Dec 18
DEF 14C
Information statement
3 Dec 17
PRE 14C
Preliminary information
21 Nov 17
DEFA14A
Additional proxy soliciting materials
22 Jun 17
DEF 14A
Definitive proxy
17 May 17
PRER14A
Preliminary revised proxy
8 May 17
PRE 14A
Preliminary proxy
7 May 17
Other
EFFECT
Notice of effectiveness
30 Sep 20
CORRESP
Correspondence with SEC
27 Sep 20
CORRESP
Correspondence with SEC
23 Sep 20
UPLOAD
Letter from SEC
22 Sep 20
EFFECT
Notice of effectiveness
20 May 20
CORRESP
Correspondence with SEC
14 May 20
CORRESP
Correspondence with SEC
14 May 20
EFFECT
Notice of effectiveness
30 Jan 20
UPLOAD
Letter from SEC
29 Jan 20
CORRESP
Correspondence with SEC
27 Jan 20
Ownership
4
WINDTREE THERAPEUTICS / Eric Curtis ownership change
8 Apr 21
4
WINDTREE THERAPEUTICS / Craig Fraser ownership change
7 Apr 21
4
WINDTREE THERAPEUTICS / Craig Fraser ownership change
6 Apr 21
4
WINDTREE THERAPEUTICS / Craig Fraser ownership change
5 Apr 21
4
WINDTREE THERAPEUTICS / James Huang ownership change
2 Apr 21
4
WINDTREE THERAPEUTICS / Craig Fraser ownership change
31 Mar 21
4
WINDTREE THERAPEUTICS / Steven Simonson ownership change
25 Mar 21
4
WINDTREE THERAPEUTICS / John P. Hamill ownership change
25 Mar 21
4
WINDTREE THERAPEUTICS / Craig Fraser ownership change
24 Mar 21
4
WINDTREE THERAPEUTICS / ROBERT A SCOTT ownership change
9 Feb 21
Reddit threads
Significant Insider Trading Activity (Last 7 Days)
9 Apr 21
Marijuana going mainstream
30 Mar 21
Daily Discussion Thread - March 30th, 2021
30 Mar 21
Daily Discussion Thread - March 29th, 2021
29 Mar 21
Daily Advice Thread - All basic help or advice questions must be posted here.
24 Mar 21
(GTII) Why is nobody talking about the GTII Short Squeeze that will be caused by April 1st? This PR is a moonshot...
23 Mar 21
Potential SWING TRADE: $WINT drops nearly 30% on public offering, hit 52 week low and currently trading UNDER offering price! New users, pay attention
23 Mar 21
THE LOUNGE: thoughts, noob stuff, low effort, brokers, zero DD, non pennies - March 23, 2021
22 Mar 21
Daily Discussion Thread - November 12th, 2020
12 Nov 20
Daily Discussion Thread - November 11th, 2020
11 Nov 20